As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.
8 Analysts have issued a Tonix Pharmaceuticals Holding Corp. forecast:
8 Analysts have issued a Tonix Pharmaceuticals Holding Corp. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 10 10 |
9%
9%
|
|
| Gross Profit | 3.53 3.53 |
51%
51%
|
|
| EBITDA | -98 -98 |
25%
25%
|
|
| EBIT (Operating Income) EBIT | -100 -100 |
21%
21%
|
|
| Net Profit | -99 -99 |
27%
27%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.
| Head office | United States |
| CEO | Seth Lederman |
| Employees | 81 |
| Founded | 2007 |
| Website | www.tonixpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


